IL32 and breast cancer: Jafarzadeh et al. evaluated the serum levels of IL-32 and reported that the IL-33 levels and IL-33/IL-12 ratio in patients with stage IV breast cancer were significantly higher compared to other stages and controls (P<0.0001 and P<0.001, respectively), revealing the contribution to breast cancer progression by the imbalance occurred in helper T (Th) cell responses Th1/Th2 [49-50].